What does CUSIP 24823R105 represent in this 13F holders report?

CUSIP 24823R105 is the security identifier for DNLI - Denali Therapeutics Inc. - Common Stock used to aggregate holder disclosures.

How many institutions held DNLI - Denali Therapeutics Inc. - Common Stock in Q4 2022?

195 institutional investors reported DNLI - Denali Therapeutics Inc. - Common Stock for Q4 2022. Use the holders table for investor-level position and value details.

Denali Therapeutics Inc. - Common Stock (DNLI)

CUSIP: 24823R105

Q4 2022 13F Holders as of 31 Dec 2022

Security type / class: Equity / Common Stock
Total 13F shares: 106,059,670
Total 13F value: $2,949,511,974
Share change: +12,864,596
Put/Call ratio: 17%
SEC-reported price per share: $27.81
Number of holders: 195
Value change: +$353,989,026
Number of buys: 107
Number of sells: 76
Shares outstanding: 159,469,733

Security key

24823R105

Report period

Q4 2022

Institutions

195

Top holders

DNLI full security history Ownership snapshot Full 13F holder table Denali Therapeutics Inc. SEC filings Denali Therapeutics Inc. company facts

Broader feeds

Latest 13F filings Latest 13D/G filings Investors directory

Ownership snapshot

Top reported holders of DNLI - Denali Therapeutics Inc. - Common Stock (13F + 13D/G + 3/4/5)

Grouped by holder across the latest SEC ownership disclosures. Start with comparable ownership when available, then verify the linked 13F, 13D/G, or 3/4/5 evidence.

Comparable stake leader

BAILLIE GIFFORD & CO

Disclosed value leader

BAILLIE GIFFORD & CO

Comparable rows

15/15

Latest evidence

30 Sep 2022

13F Lead comparable stake: 9.2% Showing 1-6 of 15 holder rows.

Quick read

BAILLIE GIFFORD & CO leads the comparable SEC ownership view at 9.2%.

15 of 15 rows have a safely comparable ownership percentage. Use this as a filing-backed starting point, then open the detailed table for source links, reporting role, position value, share count, and filing date.

Open SEC evidence Opens BAILLIE GIFFORD & CO's linked filing trail.

Comparable ownership Top 5

BAILLIE GIFFORD & CO 9.2%

BlackRock Finance, Inc. 5.4%

VANGUARD GROUP INC 5.3%

Crestline Management, L.P. 4.5%

Temasek Holdings (Private) Ltd 3.5%

Ownership % is shown only when SEC disclosures are safely comparable across share classes.

Detailed SEC evidence table Showing 1-6 of 15 holder rows

Holder	Evidence	Ownership %	Position	12M Net Δ	As of
BAILLIE GIFFORD & CO	13F Company 13F	9.2%	$451,605,000 14,715,051 shares	—	30 Sep 2022
BlackRock Finance, Inc.	13F Company 13F	5.4%	$263,880,000 8,598,212 shares	—	30 Sep 2022
VANGUARD GROUP INC	13F Company 13F	5.3%	$257,858,000 8,402,031 shares	—	30 Sep 2022
Crestline Management, L.P.	13F Company 13F	4.5%	$219,763,000 7,160,732 shares	—	30 Sep 2022
Temasek Holdings (Private) Ltd	13F Company 13F	3.5%	$171,128,698 5,576,041 shares	—	30 Sep 2022
STATE STREET CORP	13F Company 13F	2.6%	$128,659,000 4,192,228 shares	—	30 Sep 2022

How to read this table

Rows are grouped by holder and ranked first by SEC-reported ownership % when it is safely comparable, then by disclosed holdings value. — indicates unavailable or non-comparable values; "mixed-class rows" means the latest filing spans non-comparable classes.

13F holder rows

Institutional holders as of Q4 2022

Investor-level positions for this CUSIP, loaded as an interactive table.

Institutions

195

106,059,670

Rows available

195

Investor	Option	Weight %	Change %	SEC-reported value	* Price	Shares	Share Change	Activity	Report Period

^* SEC-reported price is the security price as of the portfolio date and can indicate the last known price at which the security was still held. The marker flags a reported price that did not pass the local price check.

Compare Q4 2022 vs Q3 2022 Across Filers

Q3 2022 holders

192

Q4 2022 holders

195

Holder diff

Investor	Q3 2022 Shares	Q4 2022 Shares	Share Diff	Share Chg %	Q3 2022 value	Q4 2022 value	Value change	Value Chg %